AACE/ACE Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis © 2016

Recent reports of diabetic ketoacidosis (DKA) occur-ring in conjunction with sodium glucose-cotransporter 2 (SGLT-2) inhibitor therapy have raised concerns that these agents may increase the risk of DKA, especially among patients taking exogenous insulin. On May 15, 2015, the U.S. Food and Drug Administration (FDA) issued the following safety communication concerning 20 cases of acidosis in patients taking SGLT-2 inhibitors reported to the FDA Adverse Event Reporting System